This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
The need-to-know this morning
- Moderna earnings are here.
- Gilead Sciences reported earnings last night.
What biopharma leaders think of the new Trump era
My colleagues have gathered reactions from leaders across the biopharma industry about what a second Donald Trump presidency could mean. While Trump has positioned himself as business-friendly, he’s also criticized high drug costs. And in the late stages of his campaign, he embraced Robert F. Kennedy Jr., who’s signaled he wants to shake up to the FDA and other health agencies.
Many said they’d take a wait-and-see approach, but others took a more definitive stance. “I’m optimistic,” Bausch + Lomb CEO Brent Saunders said. Meanwhile, Zach Weinberg, CEO of Curie.Bio, said that while Trump’s policies on health care have been known to shift, “R.F.K. is scary and unqualified to lead anything but a trip to the supermarket.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
